FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1556521878> ?p ?o ?g. }

• W1556521878 endingPage "217" @default.
• W1556521878 startingPage "207" @default.
• W1556521878 abstract "BACKGROUND To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen. METHODS Eligibility criteria included histologically documented, diffuse small cleaved, diffuse mixed, diffuse large cell, or immunoblastic lymphoma, Stage III–IV or bulky Stage II disease, and an ECOG performance status of 0–1. CALGB 8852, a group-wide study, accrued 227 patients: 120 patients in the pilot study to determine the maximum tolerated dose (MTD) without G-CSF and 107 in the pilot study of dose-escalated CHOPE with G-CSF. CALGB 8854, a limited-institution, Phase I study, enrolled 38 patients and determined the MTD of CHOPE with G-CSF to be used in CALGB 8852. The MTD in both studies was defined as the dose at which 50% of patients had 1) Grade 4 neutropenia or thrombocytopenia lasting 7 days or more, or 2) Grade 3–4 hemorrhage or nonhematologic toxicity (excluding alopecia, nausea, and emesis), or 3) were prevented from receiving 100% of drug on Day 22. RESULTS The MTD of CHOPE without G-CSF was cyclophosphamide 1000 mg/m2 on Day 1 and etoposide 100 mg/m2 on Days 1–3 with doxorubicin 50 mg/m2 on Day 1, vincristine 1.4 mg/m2 (maximum, 2 mg) on Day 1, and prednisone 100 mg on Days 1–5. With the addition of G-CSF at 200 μg/m2 on Days 5–19, the MTD was cyclophosphamide 1500 mg/m2 and etoposide 160 mg/m2 on Days 1–3 with standard doses of doxorubicin, vincristine, and prednisone. Increasing the dose of G-CSF from 200 μg/m2 to 400 μg/m2 did not allow for further dose escalation. The primary toxicity in all cohorts was neutropenia. Four toxic deaths occurred on CALGB 8852. The 5-year failure free survival (FFS) and overall survival (OS) rates for eligible patients on CALGB 8852 were 31% (95% confidence interval [95%CI], 23–39) and 48% (95%CI, 40–57), respectively. The 5-year FFS and OS rates for eligible patients on CALGB 8854 were 34% (95%CI, 17–52) and 51% (95%CI, 33–70), respectively. CONCLUSIONS Moderate dose escalation with G-CSF is feasible. However, response and survival rates of patients who receive dose-escalated CHOPE, even with the addition of G-CSF, appear similar to the rates reported with standard-dose CHOP. Cancer 2001;92:207–17. © 2001 American Cancer Society." @default.
• W1556521878 created "2016-06-24" @default.
• W1556521878 creator A5005446802 @default.
• W1556521878 creator A5021842242 @default.
• W1556521878 creator A5025424948 @default.
• W1556521878 creator A5052399630 @default.
• W1556521878 creator A5056482233 @default.
• W1556521878 creator A5062378578 @default.
• W1556521878 creator A5068867603 @default.
• W1556521878 creator A5070128429 @default.
• W1556521878 creator A5078808057 @default.
• W1556521878 creator A5088697255 @default.
• W1556521878 date "2001-01-01" @default.
• W1556521878 modified "2023-10-12" @default.
• W1556521878 title "Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma" @default.
• W1556521878 cites W1899525676 @default.
• W1556521878 cites W1930245694 @default.
• W1556521878 cites W1946151534 @default.
• W1556521878 cites W1997353354 @default.
• W1556521878 cites W2053704847 @default.
• W1556521878 cites W2096105848 @default.
• W1556521878 cites W2107202569 @default.
• W1556521878 cites W2142334769 @default.
• W1556521878 cites W2274586909 @default.
• W1556521878 cites W2318772898 @default.
• W1556521878 cites W4205736005 @default.
• W1556521878 cites W4252168887 @default.
• W1556521878 cites W4293241248 @default.
• W1556521878 cites W55214634 @default.
• W1556521878 doi "https://doi.org/10.1002/1097-0142(20010715)92:2<207::aid-cncr1311>3.0.co;2-d" @default.
• W1556521878 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11466671" @default.
• W1556521878 hasPublicationYear "2001" @default.
• W1556521878 type Work @default.
• W1556521878 sameAs 1556521878 @default.
• W1556521878 citedByCount "29" @default.
• W1556521878 countsByYear W15565218782012 @default.
• W1556521878 countsByYear W15565218782013 @default.
• W1556521878 countsByYear W15565218782018 @default.
• W1556521878 countsByYear W15565218782019 @default.
• W1556521878 countsByYear W15565218782020 @default.
• W1556521878 countsByYear W15565218782022 @default.
• W1556521878 crossrefType "journal-article" @default.
• W1556521878 hasAuthorship W1556521878A5005446802 @default.
• W1556521878 hasAuthorship W1556521878A5021842242 @default.
• W1556521878 hasAuthorship W1556521878A5025424948 @default.
• W1556521878 hasAuthorship W1556521878A5052399630 @default.
• W1556521878 hasAuthorship W1556521878A5056482233 @default.
• W1556521878 hasAuthorship W1556521878A5062378578 @default.
• W1556521878 hasAuthorship W1556521878A5068867603 @default.
• W1556521878 hasAuthorship W1556521878A5070128429 @default.
• W1556521878 hasAuthorship W1556521878A5078808057 @default.
• W1556521878 hasAuthorship W1556521878A5088697255 @default.
• W1556521878 hasBestOaLocation W15565218781 @default.
• W1556521878 hasConcept C126322002 @default.
• W1556521878 hasConcept C141071460 @default.
• W1556521878 hasConcept C2776694085 @default.
• W1556521878 hasConcept C2776755627 @default.
• W1556521878 hasConcept C2777063308 @default.
• W1556521878 hasConcept C2778119113 @default.
• W1556521878 hasConcept C2778720950 @default.
• W1556521878 hasConcept C2779429289 @default.
• W1556521878 hasConcept C2781413609 @default.
• W1556521878 hasConcept C71924100 @default.
• W1556521878 hasConcept C90924648 @default.
• W1556521878 hasConceptScore W1556521878C126322002 @default.
• W1556521878 hasConceptScore W1556521878C141071460 @default.
• W1556521878 hasConceptScore W1556521878C2776694085 @default.
• W1556521878 hasConceptScore W1556521878C2776755627 @default.
• W1556521878 hasConceptScore W1556521878C2777063308 @default.
• W1556521878 hasConceptScore W1556521878C2778119113 @default.
• W1556521878 hasConceptScore W1556521878C2778720950 @default.
• W1556521878 hasConceptScore W1556521878C2779429289 @default.
• W1556521878 hasConceptScore W1556521878C2781413609 @default.
• W1556521878 hasConceptScore W1556521878C71924100 @default.
• W1556521878 hasConceptScore W1556521878C90924648 @default.
• W1556521878 hasIssue "2" @default.
• W1556521878 hasLocation W15565218781 @default.
• W1556521878 hasLocation W15565218782 @default.
• W1556521878 hasOpenAccess W1556521878 @default.
• W1556521878 hasPrimaryLocation W15565218781 @default.
• W1556521878 hasRelatedWork W1921119956 @default.
• W1556521878 hasRelatedWork W1986487042 @default.
• W1556521878 hasRelatedWork W2004932524 @default.
• W1556521878 hasRelatedWork W2031021461 @default.
• W1556521878 hasRelatedWork W2044362603 @default.
• W1556521878 hasRelatedWork W2047206303 @default.
• W1556521878 hasRelatedWork W2138201596 @default.
• W1556521878 hasRelatedWork W2143831053 @default.
• W1556521878 hasRelatedWork W2399446920 @default.
• W1556521878 hasRelatedWork W4290257576 @default.
• W1556521878 hasVolume "92" @default.
• W1556521878 isParatext "false" @default.
• W1556521878 isRetracted "false" @default.
• W1556521878 magId "1556521878" @default.
• W1556521878 workType "article" @default.